Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review)

Abstract

INTRODUCTION: genetically engineered biological drugs (GIBD) used in the treatment of moderate to severe inflammatory bowel diseases (IBD) currently. Despite a significant improvement in disease outcomes, improvement in the quality of life of patients and a decrease in surgical activity, in the long term, it is often not possible to achieve full-fledged clinical and instrumental remission or the loose of response over time.OBJECTIVE: to systematize data on the efficacy and safety of IBD infliximab therapy, as well as methods of early and late efficacy assessment; indications, types and features of therapy optimization.CONCLUSIONS: despite the appearance of a relatively large number of new GIBD and TIS, the problem of inefficiency or loss of response remains. In our opinion, the solution to this problem may be the personification of the appointment and treatment regimens of GIBP. Currently, there are many studies devoted to both clinical and laboratory markers of prognostic importance in the management of patients with IBD during infliximab therapy. However, these studies are not localized for the Russian patient population. Multicenter studies on the Russian patient population are required.